Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) shot up 3.7% during mid-day trading on Tuesday . The stock traded as high as $4.01 and last traded at $3.96, with a volume of 325,326 shares changing hands. The stock had previously closed at $3.82.

Several brokerages recently issued reports on VBLT. Zacks Investment Research lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Thursday, May 5th. Roth Capital restated a “buy” rating and issued a $22.00 price objective on shares of Vascular Biogenics in a report on Thursday, June 9th. HC Wainwright began coverage on shares of Vascular Biogenics in a report on Tuesday, June 28th. They issued a “buy” rating and a $11.00 price objective on the stock. Chardan Capital restated a “buy” rating on shares of Vascular Biogenics in a report on Tuesday, June 7th. Finally, Piper Jaffray Cos. restated a “buy” rating and issued a $14.00 price objective on shares of Vascular Biogenics in a report on Tuesday, June 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $16.50.

The stock has a 50 day moving average price of $4.31 and a 200 day moving average price of $3.62. The firm’s market cap is $89.90 million.

Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.21) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.21). Equities research analysts anticipate that Vascular Biogenics Ltd. will post ($0.82) EPS for the current fiscal year.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.